However, with the exception of pancreatic and renal clear cell carcinomas and individual cases of pancreatic neuroendocrine neoplasms, our results indicate that GPER expression levels are too low in the vast majority of tumours to serve as a suitable diagnostic or therapeutic target. This evidence concerns the gene GPER1 and clear cell renal carcinoma.